OPKO Health to Participate in Upcoming September Conferences

Download as PDF

MIAMI--(BUSINESS WIRE)-- OPKO Health, Inc. (Nasdaq: OPK), today announced that senior management will participate in the 11th Annual Wells Fargo Securities Healthcare Conference taking place September 7-8, 2016 in Boston and the 9th Annual Barrington Research Fall Investment Conference taking place on September 8, 2016 in Chicago.

11th Annual Wells Fargo Securities Healthcare Conference

Date and Time: September 7, 2016, 11:05 AM EDT
Website: 2016 Wells Fargo Healthcare Conference
Format: Company presentation
Presenter: OPKO Health Senior Management

Barrington Research Fall Investment Conference

Date: September 8, 2016
Website: 9th Annual Barrington Research Fall Investment Conference
Format: One-on-One Meetings
Presenter: OPKO Health Senior Management

The 11th Annual Wells Fargo Securities Healthcare Conference presentation will be webcast on OPKO Health’s Investor Relations page of the corporate website at www.opko.com. To access the live webcast, please log on to the OPKO site approximately fifteen minutes before the presentation to register and download any necessary audio software. The audio presentation will be available at this link for a limited time after the live presentation.

About OPKO Health, Inc.

OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 420-person sales force to drive growth and leverage new products, including the 4Kscore prostate cancer test and the Claros 1 in-office immunoassay platform. Our pharmaceutical business features RAYALDEE, an FDA approved treatment for SHPT in stage 3-4 CKD patients with vitamin D insufficiency, and VARUBI™ for chemotherapy-induced nausea and vomiting (oral formulation launched by partner Tesaro and IV formulation PDUFA is January 2017). Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), a long-acting Factor VIIa drug for hemophilia (in Phase 2a) and a long acting oxyntomodulin for diabetes and obesity (in Phase 1). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy. More information is available at www.opko.com.

OPKO Health, Inc.
Tara Mackay, 305-575-4100
Investor Relations
or
Media
Rooney & Associates
Terry Rooney, 212-223-0689
trooney@rooneyco.com
or
Marion Janic, 212-223-4017
mjanic@rooneyco.com
or
Investors
LHA
Anne Marie Fields, 212-838-3777
afields@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com

Source: OPKO Health, Inc.

Released September 1, 2016